Healthcare Scan

Scan

Healthcare Scan

Scan symbols 20
SYKISRGMDTDXCMABTPFEMRKLLYGILDAMGNBIIBJNJUNHCVSVEEVTMOVRTXMRNAZTSLLY
Watchlists 1
@healthcare
raw scan snapshot — prices as of scan date, not live 38 rows · screens, not recommendations

Healthcare sector deeply bifurcated: UNH/CVS/LLY/JNJ/MRK breaking out while medtech (ISRG, ABT, SYK) and ZTS collapse — the sector is NOT homogeneous; insurers + managed care + GLP-1 pharma are winning, legacy devices are losing.

Source: healthcare.json

Quick Snapshot

Signal Reading
Overall 🟡 Healthcare divided by sub-sector — managed care (UNH +42.6% 3M, RSI 67) and biopharma (LLY, JNJ, MRK) advancing while devices (ISRG, ABT, SYK) and animal health (ZTS) in structural decline; net: favor pharma/insurer, exit devices
Leaders UNH ($407.65, RSI 67, near ATH -2%), CVS ($100.72, RSI 70, +35.8% 3M), LLY ($1122.50, RSI 60, +13.6% 30D), JNJ ($235.18, RSI 56, near ATH -6.6%)
Laggards ZTS ($79.33, RSI 37, -34.5% 3M, collapse), ISRG ($417.07, RSI 44, -13.6% 3M, deathcross), ABT ($90.62, RSI 54, -17.6% 3M), VEEV ($163.38, RSI 46, -12.5% 3M, collapse)
Key insight CVS at RSI 70 near ATH after +35.8% 3M — managed care re-rating as ACA enrollment + PBM pricing reform plays out; UNH +42.6% 3M = strongest large-cap recovery in the scan

Price Table

Stock Price RSI vs SMA20 7D% 30D% 3M% 52wkHi% Signal
ZTS $79.33 37.1 ↓ -0.1% -1.84% +2.07% -34.52% -51.73% ❌ Don't Buy
ISRG $417.07 44.1 -1.3% -2.93% -5.19% -13.61% -30.93% ❌ Don't Buy
MRK $115.17 47.4 -1.7% -3.53% +3.05% +0.11% -7.97% 🔍 Watch
GILD $127.23 46.5 -1.1% -1.01% -1.23% -11.31% -19.11% 🔍 Watch
VEEV $163.38 46.3 ↓ -2.4% -5.03% -0.29% -12.49% -47.38% ❌ Don't Buy
TMO $472.63 50.1 +0.4% -3.47% +7.04% +0.08% -26.61% 🔍 Watch
PFE $26.04 51.9 +0.7% +1.36% +2.80% -3.56% -9.43% 🔍 Watch
SYK $310.58 51.5 +0.9% -0.58% -0.84% -10.80% -23.29% 🔍 Watch
BIIB $195.61 51.7 +0.5% +1.42% +1.93% +5.57% -5.03% 🔒 Hold
MDT $81.32 57.0 +3.5% -2.18% +5.17% -7.30% -23.52% 🔍 Watch
ABT $90.62 54.3 +2.5% -3.47% +3.08% -17.63% -34.83% 🔍 Watch
DXCM $73.16 55.8 -0.1% -5.36% +12.40% +8.67% -18.69% 🔒 Hold
AMGN $347.84 55.4 +2.1% +1.50% +7.23% -2.95% -11.10% 🔒 Hold
VRTX $453.17 58.6 +3.0% +1.56% +3.80% -2.02% -10.78% 🔒 Hold
JNJ $235.18 56.2 +1.7% +1.57% +3.33% -0.66% -6.57% 🔒 Hold
LLY $1,122.50 60.3 +2.1% -2.63% +13.60% +20.86% -5.09% 🔒 Hold
MRNA $55.40 64.4 +14.8% +10.58% +15.15% +2.73% -6.97% 📈 Accumulate
UNH $407.65 66.5 +4.3% -0.13% +4.82% +42.56% -2.00% 🔒 Hold
CVS $100.72 69.9 +6.1% +4.13% +4.93% +35.81% -1.99% ⚠️ Approaching Overbought

Tier Analysis

Oversold / Collapsing (RSI < 45)

  • ZTS ($79.33, RSI 37) — Zoetis: animal health in structural collapse. -34.5% 3M, -52% from ATH. Deathcross, strong-down. DO NOT BUY — thesis broken.
  • ISRG ($417.07, RSI 44) — Intuitive Surgical: surgical robotics, -13.6% 3M, -31% from ATH. Deathcross active. Was a premium growth name, now in protracted downtrend. No entry.
  • VEEV ($163.38, RSI 46) — Veeva Systems: healthcare SaaS, -47% from ATH, collapse regime. Deathcross, strong-down. SaaS multiple re-rating unfinished.

Neutral / Basing (RSI 45–60)

  • MRK ($115.17, RSI 47) — Merck: Keytruda franchise + Gardasil; golden cross, strong-up trend. Near ATH (-8%). +52% 1Y. Basing after a strong run. Hold/accumulate on dip.
  • GILD ($127.23, RSI 46) — Gilead: HIV antivirals, -11.3% 3M, -19% from ATH. Trend "down" with golden cross. Watch for RSI < 40 entry.
  • JNJ ($235.18, RSI 56) — J&J: diversified pharma, near ATH (-6.6%), golden cross. Strong-up. Defensive large-cap with MedTech spin-off (Kenvue) simplifying the story.
  • LLY ($1,122.50, RSI 60) — Eli Lilly: GLP-1 franchise oligopoly. +13.6% 30D, near ATH (-5%), golden cross. The sector's premier compounder. Hold.
  • AMGN ($347.84, RSI 55) — Amgen: biosimilars + biologics; golden cross, strong-up, near ATH (-11%). Stable.
  • TMO ($472.63, RSI 50) — Thermo Fisher: lab tools/CROs; -26.6% from ATH, deathcross, basing. User owned name — watching.
  • BIIB ($195.61, RSI 52) — Biogen: Alzheimer's cycle, near ATH (-5%), golden cross. Strong-up. Hold.

Momentum / Approaching Overbought (RSI 60–70+)

  • MRNA ($55.40, RSI 64) — Moderna: mRNA platform re-rating. +10.6% 7D, +15.2% 30D, +43% vs SMA200. Golden cross. 1Y +113.9%. Best momentum name in the scan.
  • UNH ($407.65, RSI 67) — UnitedHealth: managed care giant, +42.6% 3M, near ATH (-2%). Golden cross, strong-up. Massive recovery after DOJ scrutiny concerns; the insurer thesis re-emerging.
  • CVS ($100.72, RSI 70) — CVS Health: pharmacy + PBM + insurance; +35.8% 3M, near ATH (-2%). RSI 70 approaching overbought but thesis intact. Trim risk if not held; don't chase.

Entry Zones

Stock Price Zone RSI 30D% Setup
LLY $1,122.50 <$1,100 60.3 +13.6% GLP-1 oligopoly; near ATH; GC; accumulate on any dip
MRK $115.17 <$115 47.4 +3.05% Keytruda franchise; near ATH (-8%); GC; pullback opportunity
GILD $127.23 <$120 46.5 -1.23% HIV antivirals; -19% from ATH; GC; watch for RSI < 40
JNJ $235.18 <$235 56.2 +3.33% Diversified pharma; near ATH; GC; core hold
MRNA $55.40 <$58 64.4 +15.2% mRNA re-rating; +43% vs SMA200; momentum is early innings

Action Matrix

Action Stocks Why
🔒 HOLD LLY, JNJ, MRK, AMGN, BIIB, VRTX, DXCM, UNH Trends intact; thesis confirmed; do not sell into strength
📈 ACCUMULATE MRNA mRNA platform re-rating; +10.6% 7D momentum; golden cross; -7% from ATH = early
🔍 WATCH GILD, TMO, PFE, MDT, ABT, SYK Pullbacks with intact theses; wait for RSI confirmation or catalyst
⚠️ AVOID / APPROACHING OVERBOUGHT CVS RSI 70, near ATH, +35.8% 3M — don't chase; wait for pullback
❌ DON'T BUY ZTS, ISRG, VEEV Broken thesis + deathcross + collapse regime; structural declines not finished

What Changed

  • UNH +42.6% 3M — UnitedHealth Group's largest multi-month run in years. Managed care thesis re-emerging as DOJ scrutiny fears faded and Medicare Advantage holds. Now near ATH, RSI 67.
  • CVS +35.8% 3M, RSI 70 — CVS transformation (pharmacy → insurance/MinuteClinic) gaining market credibility. Near ATH after a structural re-rate. Approaching overbought.
  • ZTS -34.5% 3M collapse — Zoetis animal health remains the worst name in the scan. -52% from ATH. No signs of reversal.
  • ISRG deathcross confirmed — Intuitive Surgical in structural decline. Was market darling; now in downtrend at -31% from ATH.
  • MRNA re-rating (also in biotech scan) — Confirmed across both healthcare and biotech scans: mRNA platform recovery is the most significant inflection in the sector.
  • ABT -17.6% 3M — Abbott devices weak; -35% from ATH, deathcross. Abbott Libre CGM thesis challenged by competition.
  • VEEV collapse — Veeva's healthcare SaaS multiple continues to compress; -47% from ATH, collapse regime.
  • JNJ strong — J&J near ATH with golden cross; spinning off consumer (Kenvue) simplified the investment thesis for institutional buyers.
  • PFE basing — Pfizer at RSI 51 near ATH (-9.4%), golden cross. Post-COVID pipeline diversification + antiviral slate. No urgency but thesis stabilizing.

Key Discoveries

Discovery Implication
UNH + CVS both strong vs ZTS + ISRG both collapsed Healthcare sub-sector rotation: insurers winning, device makers losing
MRNA confirmed across both healthcare + biotech scan Dual-scan confirmation = mRNA re-rating is sector-wide signal, not single-scan noise
JNJ near ATH while ISRG/ABT/SYK all down 14-31% Diversified pharma outperforming focused medtech in this tape

Mistakes (Don't Repeat)

Mistake Lesson
Treating ISRG as a forever-hold premium growth name Surgical robotics has competition risk (J&J Ottava, Medtronic Hugo) — deathcross was the warning
Chasing ZTS as an animal health defensive Animal health has idiosyncratic disease risk; not a true defensive

Open Questions

  • Is UNH's +42.6% 3M recovery complete, or does it continue into Medicare Advantage enrollment season?
  • VEEV at -47% from ATH: is the healthcare SaaS multiple trough near, or still has more to compress?
  • ABT Libre vs Dexcom DXCM — both showing weakness; is the CGM market oversupplied?
10 events
DateTypeEvent
Jun 20 ScanHealthcare Scan Jun 25 ScanHealthcare Scan Jun 26 ScanHealthcare Scan May 29 ScanHealthcare Scan Jul 11 ScanHealthcare Scan Jul 7 ScanHealthcare Scan Jul 17 ScanHealthcare Scan Jul 25 ScanHealthcare Scan Jul 28 ScanHealthcare Scan Jul 31 ScanHealthcare Scan

No direct external sources are attached to this read.